超敏C反应蛋白与冠心病发病的相关性分析

目的探讨超敏C反应蛋白与冠心病发病的相关性。方法选择103例疑诊冠心病并行冠脉造影检查的病例,分为冠心病组61例和对照组42例,检测超敏C反应蛋白水平。结果冠心病组超敏C反应蛋白水平显著高于对照组分别为(0.961±0.814)mg/L与(0.156±0.412)mg/L,两组差异有统计学意义(P0.05);相关分析显示超敏C反应蛋白与冠脉狭窄指数呈正相关(P0.05);多元Logistic回归分析显示冠心病的发病与超敏C反应蛋白有关。结论超敏C反应蛋白与冠心病密切相关,是其独立危险因素之一。     

超敏C反应蛋白与Framingham评分预测高血压前期颈动脉内中膜增厚的临床价值

目的观察超敏C反应蛋白对高血压前期颈动脉内中膜厚度的影响,探讨超敏C反应蛋白与Framingham评分预测高血压前期颈动脉内中膜增厚的临床价值。方法选择2018年2月—2018年10月山西医科大学第二临床医学院门诊与体检中心病人230例,根据血压分为对照组(50例)与高血压前期组(180例)。比较两组一般资料、检测生化指标及超敏C反应蛋白,计算Framingham评分,行颈动脉超声测量颈动脉内中膜厚度。结果高血压前期组超敏C反应蛋白、颈动脉内中膜厚度、Framingham评分均高于对照组,差异有统计学意义(P0.01)。以颈动脉内中膜厚度为因变量行多元逐步回归分析发现,超敏C反应蛋白是独立影响因素。以工作特征曲线并行Z检验比较结果显示:超敏C反应蛋白联合Framingham预测颈动脉内中膜增厚诊断特异性优于单独Framingham评分和超敏C反应蛋白。结论高血压前期已出现动脉粥样硬化早期表现,心血管疾病风险增加,超敏C反应蛋白在高血压前期人群动脉粥样硬化发生中具有独立机制,且超敏C反应蛋白联合Framingham评分可较好地预测高血压前期颈动脉内中膜增厚的发生。     

糖化血红蛋白和超敏C反应蛋白在预测2型糖尿病患者心房颤动中的价值研究

目的探讨分析糖化血红蛋白、超敏C反应蛋白在预测2型糖尿病患者心房颤动中的价值。方法随机选取2014年5月—2018年5月期间于该院诊断为2型糖尿病并住院治疗的患者55例做为对照组,2型糖尿病合并房颤并住院治疗的的患者55例作为观察组,测定两组患者血清糖化血红蛋白、超敏C反应蛋白水平和左房内径,对比分析三项指标之间的关系。结果观察组患者的糖化血红蛋白、超敏C反应蛋白水平及左房内径均高于对照组,差异有统计学意义(P0.05);糖化血红蛋白、超敏C反应蛋白水平之间存在明显正相关;糖化血红蛋白、超敏C反应蛋白水平分别与左房内径呈明显正相关。结论 2型糖尿病患者血清中糖化血红蛋白、超敏C反应蛋白水平水平越高,合并房颤的发生率越高,联合检测血清糖化血红蛋白、超敏C反应蛋白水平更利于预测2型糖尿病患者房颤的发生风险。     

胱抑素C和超敏C反应蛋白联合检测诊断糖尿病早期肾损害的价值分析

目的研究联合使用胱抑素C和超敏C反应蛋白的检测方法诊断糖尿病早期肾损害的诊断效果。方法选择该院2017年6月-2019年6月收治的80例糖尿病早期肾损害患者作为该次研究入组对象,另随机选取同期单纯糖尿病患者及正常体检志愿者作为对照组,每组80例,采用免疫比浊法检测胱抑素C和超敏C反应蛋白水平,统计并分析比较3组之间的数据结果。结果胱抑素C以及超敏C反应蛋白在糖尿病早期肾损害组的水平明显高于糖尿病肾功能正常组及健康对照组,数据差异有统计学意义(P<0.05)。胱抑素C和超敏C反应蛋白联合检测的阳性率显著高于胱抑素C和超敏C反应蛋白单一指标,差异有统计学意义(P<0.05)。结论胱抑素C和超敏C反应蛋白联合检测诊断糖尿病早期肾损害比单一指标检测具有更好的诊断价值,值得临床推广。     

血尿酸与超敏C反应蛋白水平检测在高血压病情评估中的应用分析

目的探讨在高血压病情评估中运用血尿酸与超敏C反应蛋白水平检测的效果。方法将内科80例高血压患者(2017年1月到2018年10月间收治)设为高血压组,将同期80例健康体检人员设为健康组,对所有人员均实施血尿酸、超敏C反应蛋白水平检测,分析总结不同人员的检测结果。结果高血压组患者血尿酸、超敏C反应蛋白水平显著高于健康组(P0.05)。高血压组中分级Ⅰ级、Ⅱ级、Ⅲ级患者血尿酸、超敏C反应蛋白水平差异显著(P0.05)。高血压组中颈动脉内膜正常、内膜增厚、斑块形成、管腔狭窄患者血尿酸、超敏C反应蛋白水平差异显著(P0.05)。结论在高血压中运用血尿酸与超敏C反应蛋白水平检测可有效辅助患者病情评估,且通过血尿酸与超敏C反应蛋白水平了解患者血管病变状况,辅助并发症风险评估。     

超敏C反应蛋白水平在妊娠期妇女糖尿病发展过程中的意义

目的考察超敏C反应蛋白水平在妊娠期妇女糖尿病发展过程中的意义。方法收集2010年3月到2012年9月在本院妇产科诊治的妊娠期妇女共102例,分为35例正常糖耐量孕妇组、32例妊娠期糖耐量受损孕妇组及35例妊娠糖尿病孕妇组血清超敏C反应蛋白水平,并将同期体检健康的女性39例作为对照。结果与健康对照组比,正常妊娠组的空腹血糖和超敏C反应蛋白差异无统计意义(P>0.05);与正常妊娠组比,糖耐量受损孕妇组和糖尿病孕妇组的空腹血糖和超敏C反应蛋白明显增高(P<0.05);与糖耐量受损孕妇组比,糖尿病孕妇组的空腹血糖和超敏C反应蛋白更高(P<0.05)。结论超敏C反应蛋白升高可预测妊娠糖尿病发病。     

监测超敏C反应蛋白与2型糖尿病下肢血管病变探讨

目的研究通过观察T2DM患者血清超敏C反应蛋白水平,同时与下肢血管病变情况对比,探讨超敏C反应蛋白在T2DM下肢血管病变中的相关性。方法将120名2型糖尿病患者根据下肢多普勒超声分为下肢动脉硬化组和下肢动脉非硬化组二组。分别检测二组患者血清超敏C反应蛋白,空腹血糖(FBG),糖化血红蛋白(HbA.C),血脂(TC、TG、HDL。C、LDL-C)等指标。结果下肢动脉硬化组收缩压、FBG、FIB、超敏C反应蛋白、HOMA_IR较非下肢动脉硬化组组增高,差异有统计学意义。二组之间差异有统计学意义(P相似文献   

超敏C反应蛋白检测在缺血性脑卒中诊治中的价值

目的：探讨超敏C反应蛋白在缺血性脑卒中患者诊治中的价值。方法选取120例缺血性脑卒中患者为疾病组,根据梗死程度的不同,将其分为轻度梗死47例,中度梗死35例,重度梗死38例;同时选择同期性别、年龄等一般资料近似的120名健康体检者设为对照组。检测所有疾病组患者治疗前后及健康体检者的超敏C反应蛋白,并比较分析检测结果,评价超敏C反应蛋白在缺血性脑卒中诊治中的价值。结果健康体检者、治疗前轻度梗死者、中度梗死者、重度梗死者的超敏C反应蛋白水平分别为（3.32±0.46） mg/L、（8.87±3.72）mg/L、（18.52±6.33）mg/L、（32.51±11.25）mg/L。缺血性脑卒中患者的超敏C反应蛋白水平明显高于健康体检受试者,且随着脑卒中梗死程度的加重,超敏C反应蛋白水平越高,组间比较差异均具有统计学意义（ P＜0.05）。治疗结束后患者的超敏C反应蛋白水平基本回复到正常水平。结论超敏C反应蛋白检测具有灵敏度高且快速的优点,可用于缺血性脑卒中患者的临床诊断及治疗效果评价。     

冠心病患者同型半胱氨酸超敏C反应蛋白的水平变化及临床意义

目的研究分析冠心病患者同型半胱氨酸和超敏C反应蛋白水平变化以及临床意义。方法随机抽取2016年1月至2017年1月期间我院收治的80名冠心病患者作为观察组,选取同期在我院进行健康体检的80例作为对照组,对两组患者的同型半胱氨酸和超敏C反应蛋白水平进行监测对比分析。结果观察组的同型半胱氨酸和超敏C反应蛋白检查结果均高于对照组,两组比较有统计学意义(P0.05)。并且随着病情加重,同型半胱氨酸和超敏C反应蛋白水平增高。结论同型半胱氨酸和超敏C反应蛋白水平对冠心病患者病情的治疗以及判断病情发展有重要临床意义。     

急性冠状动脉综合征患者血清超敏C反应蛋白及抵抗素浓度与罪犯病变虚拟组织学-血管内超声特点的相关性

目的 通过分析急性冠状动脉综合征（ACS）患者血清超敏C反应蛋白及抵抗素浓度与罪犯病变虚拟组织学-血管内超声（VH-IVUS）特点相关性,研究血清超敏C反应蛋白及抵抗素影响斑块易损性的机制.方法 选取ACS患者60例,运用酶联免疫分析法（ELISA法）检测血清抵抗素浓度及血清超敏C反应蛋白浓度.结合心电图检查ST-T发生改变的导联,超声心动图出现室壁运动异常的节段以及冠状动脉造影发现复杂病变的部位确定罪犯病变.从而研究ACS患者血清抵抗素及超敏C反应蛋白浓度与ACS罪犯病变VH-IVUS特点的相关性.结果 超敏C反应蛋白浓度的中位数为3.66 mg/L,四分位数间距为2.21 mg/L.抵抗素浓度的中位数为3.53 mg/L,四分位数间距为6.28 mg/L.ACS患者血清抵抗素浓度与罪犯病变坏死核心体积绝对值呈正相关（r=0.427,P=0.01）;ACS患者血清超敏C反应蛋白浓度与罪犯病变坏死核心体积绝对值也呈正相关（r=0.322,P=0.01）.结论 ACS患者血清超敏C反应蛋白及抵抗素浓度的增加都伴随着罪犯病变脂质池的扩大.血清抵抗素浓度在评价斑块易损性方面可能较血清超敏C反应蛋白浓度更加敏感.     

High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease

High-sensitivity C-reactive protein levels have received widespread attention because of a multitude of prospective studies that have shown that high levels of high-sensitivity C-reactive protein identify increased risk of initial cardiovascular events in coronary heart disease patients and increased risk of recurrent cardiac events in patients with stable and unstable angina, patients with acute myocardial infarction, and patients undergoing elective coronary revascularization procedures. In contrast to several other inflammatory markers, high-sensitivity C-reactive protein measurements are standardized and reproducible. The clinical significance of a reliable inflammatory marker includes identification of high-risk individuals, a gauge to monitor the activity of the disease, and a potential therapeutic target to alter the inflammatory component of the disease process. This review focuses on the importance of high-sensitivity C-reactive protein in cardiovascular risk stratification in coronary heart disease patients and discusses several preventive therapies that may reduce cardiovascular risk through reduction in high-sensitivity C-reactive protein.     

Effect of antispastic agents (calcium antagonists and/or isosorbide dinitrate) on high-sensitivity C-reactive protein in patients with coronary vasospastic angina pectoris and no hemodynamically significant coronary artery disease

Levels of high-sensitivity C-reactive protein were measured before and after 3 months of treatment with antispastic agents (calcium antagonists and/or isosorbide dinitrate) in 27 patients who had coronary vasospastic angina pectoris and no hemodynamically significant coronary artery disease. Levels of high-sensitivity C-reactive protein decreased after treatment with antispastic agents.     

不同剂量辛伐他汀对慢性缺血性心脏病合并阵发性心房纤颤C反应蛋白及心电图的影响研究

目的 观察不同剂量辛伐他汀对缺血性心脏病合并阵发性房颤病人窦性心律的维持及C反应蛋白、P波离散度、P波最长时限的影响.方法 选取缺血性心脏病合并阵发性房颤病人76例,随机分为空白对照组、辛伐他汀10mg/d组、辛伐他汀20mg/d组和辛伐他汀30mg/d组;观察24周内心房纤颤复发的病例数及次数、高敏C反应蛋白、P波离散度、P波最长时限、LDL-C、HDL-C等在治疗前后的变化.结果 与空白对照组比较,不同剂量辛伐他汀组的阵发性房颤窦性维持率均增加,且随着剂量的递增而递增;与治疗前比较,不同剂量的辛伐他汀组治疗后的高敏C反应蛋白、P波离散度、P波最长时限、LDL-C水平均降低,HDL-C水平升高;治疗后的高敏C反应蛋白的降低与给予的辛伐他汀的剂量呈负相关.结论 辛伐他汀在减少房颤的发生率及增加窦性心律的维持率的同时,也降低高敏C反应蛋白、P波离散度、P波最长时限、LDL-C水平,升高HDL-C水平,且随着辛伐他汀剂量的递增,高敏C反应蛋白也相应递减.     

Effect of CC chemokine receptor 2 CCR2 blockade on serum C-reactive protein in individuals at atherosclerotic risk and with a single nucleotide polymorphism of the monocyte chemoattractant protein-1 promoter region

CC chemokine receptor 2 (CCR2), expressed on the surface of circulating monocytes, and its ligand monocyte chemoattractant protein-1 (MCP-1; also known as CC-chemokine ligand 2) are present in atherosclerotic plaques and may have important roles in endothelial monocyte recruitment and activation. MLN1202 is a highly specific humanized monoclonal antibody that interacts with CCR2 and inhibits MCP-1 binding. The aim of this randomized, double-blind, placebo-controlled study was to measure reductions in circulating levels of high-sensitivity C-reactive protein, an established biomarker of inflammation associated with coronary artery disease, on MLN1202 treatment in patients at risk for atherosclerotic cardiovascular disease (≥2 risk factors for atherosclerotic cardiovascular disease and circulating high-sensitivity C-reactive protein >3 mg/L). Additionally, patients were genotyped for the 2518 A→G polymorphism in the promoter of the MCP-1 gene to investigate the correlation between this polymorphism and reduced C-reactive protein levels with MLN1202 treatment. Patients who received MLN1202 exhibited significant decreases in high-sensitivity C-reactive protein levels, beginning at 4 weeks and continuing through 12 weeks after dosing. Patients with A/G or G/G genotypes in the MCP-1 promoter had significantly greater reductions in high-sensitivity C-reactive protein levels than patients with the wild-type A/A genotype. In conclusion, MLN1202 treatment was well tolerated in this patient population and resulted in significant reductions in high-sensitivity C-reactive protein levels.     

The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidemic obese patients

It is now well documented that obesity is associated with a chronic low-grade inflammatory state. Levels of high-sensitivity C-reactive protein, a marker of systemic inflammation and a mediator of atherothrombotic disease, have been shown to correlate with cardiovascular disease risk. Our objective was to evaluate the effect of fenofibrate on the levels of high-sensitivity C-reactive protein in dyslipidemic obese patients. We selected 30 dyslipidemic obese patients (body mass index > or = 30 kg/m2) and 20 normolipidemic, nonobese healthy subjects. Dyslipidemic obese patients were treated with fenofibrate 200 mg/day for 3 months. Serum high-sensitivity C-reactive protein and metabolic parameters were evaluated at baseline in both groups and after fenofibrate treatment in dyslipidemic obese patients. At baseline, significantly higher high-sensitivity C-reactive protein levels were found in dyslipidemic obese patients than normal subjects (0.58+/-0.3 vs 0.14+/-0.1 mg/dL, P < 0.01). Total cholesterol, low-density lipoprotein cholesterol, and triglyceride decreased significantly (P < 0.05, P < 0.05, and P < 0.01, respectively), and levels of high-density lipoprotein cholesterol significantly increased (P < 0.05) after treatment with fenofibrate in the dyslipidemic obese group. Levels of high-sensitivity C-reactive protein decreased significantly (approximately 74.1%) after fenofibrate treatment from a mean of 0.58+/-0.3 mg/dL to 0.15+/-0.2 mg/dL, P < 0.01. Our findings suggest that fenofibrate may be used as a first-line therapy for improving the plasma lipids profile, as well as the chronic low-grade inflammatory state in dyslipidemia and obesity.     

High-sensitivity C-reactive protein predicts target organ damage in Chinese patients with metabolic syndrome

Observational studies established high-sensitivity C-reactive protein as a risk factor for cardiovascular events in the general population. The goal of this study was to determine the relationship between target organ damage and high-sensitivity C-reactive protein in a cohort of Chinese patients with metabolic syndrome. A total of 1082 consecutive patients of Chinese origin were screened for the presence of metabolic syndrome according to the National Cholesterol Education Program's Adult Treatment Panel III. High-sensitivity C-reactive protein and target organ damage, including cardiac hypertrophy, carotid intima-media thickness, and renal impairment, were investigated. The median (25th and 75th percentiles) of high-sensitivity C-reactive protein in 619 patients with metabolic syndrome was 2.42 mg/L (0.75 and 3.66 mg/L) compared with 1.13 mg/L (0.51 and 2.46 mg/L) among 463 control subjects (P < .01). There was a progressive increase in high-sensitivity C-reactive protein level with the number of components of the metabolic syndrome. Stratification of patients with metabolic syndrome into 3 groups according to their high-sensitivity C-reactive protein concentrations (<1.0, 1.0-3.0, and >3.0 mg/L) showed that the subjects with the elevated high-sensitivity C-reactive protein had a higher percentage of target organ damage than those with lower high-sensitivity C-reactive protein. Stepwise multiple logistic regression confirmed that high-sensitivity C-reactive protein was significantly associated with cardiac hypertrophy, carotid intima-media thickness, and renal impairment. The study shows a strong independent association between inflammation and target organ damage in a large cohort of patients of Chinese origin with metabolic syndrome.     

Potential role of adipocytokine leptin in acute coronary syndrome

By activating immune cells or a direct action on the vascular wall, leptin may affect the initiation and progression of atherosclerosis. We investigated whether plasma leptin concentration is associated with coronary artery disease, with particular focus on the relationship between plasma leptin and the development of an acute coronary syndrome. Plasma leptin, interleukin-6 and high-sensitivity C-reactive protein were measured in 34 patients with acute coronary syndrome and 21 with stable angina. Their results were compared with those of 21 normal controls. Plasma leptin levels were significantly higher in the acute coronary syndrome group (13.36 +/- 5.02 ng.mL(-1)) compared to the stable angina group (8.97 +/- 4.06 ng.mL(-1)) or normal controls (5.14 +/- 2.75 ng.mL(-1)). Interleukin-6 and high-sensitivity C-reactive protein were also higher in the acute coronary syndrome group, and leptin correlated positively with interleukin-6 and high-sensitivity C-reactive protein. These findings suggest that plasma leptin levels may be a useful marker of systemic inflammation, and measurement of plasma leptin may be helpful in assessing the risk of developing coronary heart disease.     

Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events

PURPOSE OF REVIEW: Inflammation plays a central role in the initiation, progression, and destabilization of vascular atheroma. In an attempt to improve global cardiovascular risk assessment, considerable research has focused on markers of inflammation; in particular, high-sensitivity C-reactive protein, a pentraxin innate immune recognition molecule and classic acute-phase reactant. RECENT FINDINGS: Multiple prospective studies now demonstrate that high-sensitivity C-reactive protein is a potent predictor of future cardiovascular events at all levels of low-density lipoprotein cholesterol, all levels of the Framingham Risk Score, and all levels of severity of the metabolic syndrome. Moreover, high-sensitivity C-reactive protein appears to be implicated in acute coronary syndromes and provides prognostic information on vascular risk among patients with renal dysfunction. In clinical settings, high-sensitivity C-reactive protein levels more than 3 mg/L are associated with the highest vascular risk. SUMMARY: High-sensitivity C-reactive protein evaluation has recently been endorsed by the Centers for Disease Control and Prevention and by the American Heart Association to be used in conjunction with lipid evaluation as part of global risk prediction. Emerging evidence further suggests that high-sensitivity C-reactive protein can be used to target pharmacologic and lifestyle interventions designed to prevent first as well as recurrent cardiovascular events.     

高敏C反应蛋白与动脉粥样硬化

采用超敏感方法检测到的C反应蛋白被称为高敏C反应蛋白.高敏C反应蛋白在冠心病、中风、周围血管栓塞等疾病诊断和预测中发挥越来越重要的作用.越来越多的研究揭示了C反应蛋白直接参与了炎症与动脉粥样硬化等心血管疾病,并且是心血管疾病最强有力的预示因子与危险因子之一.各种炎症、组织感染损伤均会引起循环中多种血浆蛋白水平增加,其中C反应蛋白作为一种急性期反应蛋白,其水平增高是体内炎症的敏感指标.而炎症在动脉粥样硬化及心血管相关疾病的发生和发展过程中都起着重要的作用.本文将高敏C反应蛋白和动脉粥样硬化之间的关系及其机制进行综述.     

Role of C-Reactive Protein in Contributing to Increased Cardiovascular Risk in Metabolic Syndrome

Metabolic syndrome is associated with increased propensity for diabetes and cardiovascular disease. Low-grade inflammation is characteristic of metabolic syndrome. C-reactive protein, the best characterized biomarker of inflammation, is also an independent predictor of future cardiovascular events. This review outlines the role of high-sensitivity C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome by inducing endothelial cell dysfunction and activating monocytes.